Clinical Trials Logo
  1. Home
  2. Lung Neoplasm Malignant
  3. NCT05890872

Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer — AFFINITY  

Lung Neoplasm Malignant Clinical Trial

Official title:
A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced Cancer

Clinical Trial Summary

The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.

Clinical Trial Description

The Aliya Treatment System is designed to deliver therapeutic PEF energy to target tissues, via either a percutaneous or bronchoscopic approach. In order to evaluate the therapeutic potential of PEF delivered via the Aliya Treatment System as an interventional treatment, this clinical trial will evaluate the safety of delivering Aliya PEF in non-surgical advanced stage disease treatment-naïve patients indicated for diagnostic biopsy and first line (1L) standard of care (SOC) therapy. Additionally, this study will examine the safety of adding PEF treatment to the care pathway for patients with metastatic cancer to the lung or stage IV NSCLC and further assess the potential immune modulation and treatment effect of PEF for providing benefit to oncological patients, as outlined below. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05890872
Study type Interventional
Source Galvanize Therapeutics, Inc.
Contact Partha Seshaiah, PhD
Phone 650-268-4252
Email pseshaiah@galvanizetx.com
Status Recruiting
Phase N/A
Start date September 6, 2023
Completion date July 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05974475 - MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
Recruiting NCT06079970 - Confocal Laser Endomicroscopy VERification N/A
Recruiting NCT04973293 - Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer N/A
Recruiting NCT04778826 - Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy N/A
Suspended NCT04036721 - Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis Phase 4
Completed NCT03352245 - Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer N/A
Completed NCT03834116 - Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies N/A
Completed NCT03824977 - Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
Terminated NCT02985203 - Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer Phase 2
Recruiting NCT06440616 - Benefit of Spectral Information in Patients Suspected for Lung Cancer N/A
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT05404022 - Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years N/A
Not yet recruiting NCT05414188 - Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy N/A
Recruiting NCT03525782 - Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC Phase 1/Phase 2
Completed NCT04059887 - Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] Phase 4
Terminated NCT05013554 - Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors Phase 1